A randomised, double-blind, placebo-controlled, multiple dose, time-lagged cohort, dose-escalation trial, investigating the pharmacodynamics, safety and tolerability, and the pharmacokinetics of PSN357AB in patients with type-2 diabetes.
Phase of Trial: Phase II
Latest Information Update: 17 May 2011
At a glance
- Drugs ATX 09-002 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- 17 May 2011 New trial record